Unique Cutaneous Reaction to Second- and Third-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia.

@article{Patel2016UniqueCR,
  title={Unique Cutaneous Reaction to Second- and Third-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia.},
  author={Anisha B. Patel and Alvin R Solomon and Michael J Mauro and Benjamin D. Ehst},
  journal={Dermatology},
  year={2016},
  volume={232 1},
  pages={122-5}
}
BACKGROUND Recently developed tyrosine kinase inhibitors (TKIs) offer first-line alternatives to patients with chronic myeloid leukemia. While these medications are generally well tolerated, cutaneous reactions occur frequently and can present a management challenge. We describe a newly recognized skin reaction to dasatinib and nilotinib and extend it to the newer agent ponatinib. OBSERVATIONS Nine patients developed varying degrees of a clinically and histopathologically lichenoid exanthem… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 16 references

Similar Papers

Loading similar papers…